The multiplicity of serotonin receptors: Uselessly diverse molecules or an embarrassment of riches?

Neuroscientist

Volumn 6, Issue 4, 2000, Pages 252-262

  Roth, Bryan L ^a,b   Lopez, Estelle ^a   Patel, Shamil ^a   Kroeze, Wesley K ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Antipsychotic; Clozapine; Fluoxetine; Serotonin receptors

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BUSPIRONE; CISAPRIDE; CLOZAPINE; FLUOXETINE; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; ONDANSETRON; PINDOLOL; RECEPTOR SUBTYPE; RITANSERIN; RO 630563; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANXIETY NEUROSIS; CHRONIC PAIN; DEPRESSION; DEVELOPMENTAL DISORDER; DRUG RECEPTOR BINDING; EATING DISORDER; HEADACHE; HUMAN; HYPERTENSION; MENTAL DISEASE; MIGRAINE; MOLECULAR CLONING; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSESSION; REVIEW; SCHIZOPHRENIA;

EID: 0033861845     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385840000600408     Document Type: Review

References (104)

1. Rapport MM. The discovery of serotonin. Perspect Biol Med 1997;40:260-73.
2. Wooley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci U S A 1954;40:228-31.
3. Roth BL, Meltzer H. The role of serotonin in schizophrenia. In: Bloom F, Kupfer D, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995. p. 1215-27.
4. Peroutka SJ, Snyder SH. Multiple serotonin receptors: differen-tial binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 1979;16:687-99.
5. Kroeze WK, Roth BL. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol Psychiatry 1998;44:1128-42.
6. Raymond JR, Albers FJ, Middleton JP. Functional expression of human 5-HT1A receptors and differential coupling to second messengers in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 1992;346:127-37.
7. Fargin A, Raymond JR, Regan JW, Cotecchia S, Lefkowitz RJ, Caron MG. The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 1988;335:358-60.
8. Chaput Y, de Montigny C, Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1986;333:342-8.
9. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991;5:219-29.
10. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996;19:378-83.
11. Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999;45:1170-7.
12. Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety disorders. Am J Psychiatry 1979;136:1184-7.
13. Wells BG, Chu CC, Johnson R, Nasdahl C, Ayubi MA, Sewell E, et al. Buspirone in the treatment of posttraumatic stress disorder. Pharmacotherapy 1991;11:340-3.
14. Rickles K, Amsterdam JD, Clary C, Puzzoli G, Schweizer E. Buspirone in the treatment of depression: a controlled study. J Clin Psychiatry 1991;52:34-8.
15. Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol 1996;11:37-44.
16. Hamblin MW, Metcalf MA, McGuffin RW, Karpells S. Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity. Biochem Biophys Res Commun 1992;184:752-9.
17. Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR. Human serotonin ID receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A 1992;89:3630-4.
18. Schoeffter P, Hoyer D. How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1989;340:135-8.
19. Peroutka SJ, McCarthy BG. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol 1989;163:133-6.
20. Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1988;1:1309-11.
21. Pauwels PJ, John GW. Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol 1999;22:123-36.
22. Saudou F, Amara DA, Dierich A, LeMeur M, Ramboz S, Segu L, et al. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science 1994;265:1875-8.
23. Lucas JJ, Segu L, Hen R. 5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptaminelB knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Mol Pharmacol 1997;51:755-63.
24. Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F, Hen R. Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin IB receptor knock-out mice. J Neurosci 1998;18:5537-44.
25. Scearce-Levie K, Viswanathan SS, Hen R. Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology (Berl) 1999;141:154-61.
26. Pineyro G, Castanon N, Hen R, Blier P. Regulation of [3H]5-HT release in raphe, frontal cortex and hippocampus of 5-HT1B knock-out mice. Neuroreport 1995;7:353-9.
27. Leonhardt S, Herrick-Davis K, Titeler M. Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem 1989;53:465-71.
28. McAllister G, Charlesworth A, Snodin C, Beer MS, Noble AJ, Middlemiss DN, et al. Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth SHT1-like subtype. Proc Natl Acad Sci U S A 1992;89:5517-21.
29. Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996;50:219-23.
30. Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME, et al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997;8:2237-40.
31. Johnson KW, Phebus LA, Cohen ML. Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res 1998:51:219-44.
32. John GW, Pauwels PJ, Perez M, Halazy S, Le Grand B, Verscheure Y, et al. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. J Pharmacol Exp Ther 1999;290:83-95.
33. Matz R, Rick W, Oh D, Thompson H, Gershon S. Clozapine-a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res 1974;16:687.
34. Andree TH, Mikuni M, Tong CY, Koenig JI, Meltzer HY. Differential effect of subchronic treatment with various neuroleptic agents on serotonin 2 receptors in rat cerebral cortex. J Neurochem 1986;46:191-7.
35. Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-46.
36. Rasmussen K, Aghajanian GK. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology 1988;1:101-7.
37. 2A receptors in atypical antipsychotic drug actions. Neuroscientist 1999;5:254-62.
38. Miller RJ, Hiley CR. Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature (Lond) 1974;248:546-7.
39. Cohen BM, Lipinski JF. In vivo potencies of antipsychotic drugs in blocking alpha1 noradrenergic and dopamine D-2 receptors: implications for drug mechanisms of action. Life Sci 1986;39:2571-86.
40. Hertel P, Fagerquuist M, Svensson T. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2-adrenoceptor blockade. Science 1999;286:105-7.
41. Van Tol HHM, Bunzow JR, Guan HC, Sunahara H-C, Seeman P, Niznik HB, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-14.
42. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) 1995;120:365-8.
43. Roth BL, Ciaranello RD, Meltzer HY. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 1992;260:1361-5.
44. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-10.
45. Sorensen SM, Kehne JH, Fadayl EM, Humphreys TM, Ketteler HJ, Sullivan C, et al. Characterization of the 5-HT2 antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 1993;266:684-91.
46. Glennon RA, Titler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984;35:2505-11.
47. Sanders-Bush E, Burris KD, Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 1988;246:924-8.
48. Grailhe R, Waeber C, Dulawa SC, Hornung JP, Zhuang X, Brunner D, et al. Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(SA) receptor. Neuron 1999;22:581-91.
49. Kursar JD, Nelson DL, Wainscott DB, Baez M. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol Pharmacol 1994;46:227-34.
50. Cohen ML, Fludzinski LA. Contractile serotonergic receptor in rat stomach fundus. J Pharmacol Exp Ther 1987;243:264-9.
51. Choi DS, Colas JF, Kellermann O, Loric S, Launay JM, Rosay P, et al. The mouse 5-HT2B receptor: possible involvement in trophic functions of serotonin. Cell Mol Biol (Noisy-le-grand) 1994;40:403-11.
52. Ellis ES, Byrne C, Murphy OE, Tilford NS, Baxter GS. Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol 1995;114:400-4.
53. Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the procine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol 1984;106:539-46.
54. Julius D, Huang KN, Livelli TJ, Axel R, Jessell TM. The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc Natl Acad Sci U S A 1990;87:928-32.
55. Choudhary MS, Craigo S, Roth BL. Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors. Mol Pharmacol 1992;42:627-33.
56. Kennett GA, Wood MD, Glen A, Grewal S, Forbes I, Gadre A, et al. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 1994;111:797-802.
57. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors [see comments]. Nature 1995;374:542-6.
58. Vickers SP, Clifton PG, Dourish CT, Tecott LH. Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl) 1999;143:309-14.
59. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene [see comments]. Nat Med 1998;4:1152-6.
60. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, et al. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998;286:913-24.
61. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, et al. RS-102221: a novel high affinity and selective 5-HT2C receptor antagonist. Neuropharmacology 1997;36:621-9.
62. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997;36:609-20.
63. Halford JC, Lawton CL, Blundell JE. The 5-HT2 receptor agonist MK-212 reduces food intake and increases resting but prevents the behavioural satiety sequence. Pharmacol Biochem Behav 1997;56:41-6.
64. Samanin R, Garattini S. Pharmacology of ingestive behaviour. Therapie 1996;51:107-15.
65. Kennett GA, Pittaway K, Blackburn TP. Evidence that 5-HT2c receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology (Berl) 1994;114:90-6.
66. Kennett GA, Whitton P, Shah K, Curzon G. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 1989;164:445-54.
67. Whitton P, Curzon G. Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology 1990;100:138-40.
68. Germine M, Goddard AW, Woods SW, Charney DS, Heninger GR. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 1992;32:457-61.
69. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, et al. m-Chlorophenylpiperazine (MCPP) effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993;50:624-35.
70. Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, et al. A comparison of the behavioral effects of oral verses intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry 1993;33:3-14.
71. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, et al. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) 1996;126:234-40.
72. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997;387:303-8.
73. Liu Y, Emeson RB, Samuel CE. Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1. J Biol Chem 1999;274:18351-8.
74. Rueter SM, Dawson TR, Emeson RB. Regulation of alternative splicing by RNA editing. Nature 1999;399:75-80.
75. Niswender CM, Sanders-Bush E, Emeson RB. Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann N Y Acad Sci 1998;861:38-48.
76. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 1999;274:9472-8.
77. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999;397:359-63.
78. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991;254:432-7.
79. Bloom FE, Morales M. The central 5-HT3 receptor in CNS disorders. Neurochem Res 1998;23:653-9.
80. Dumuis A, Sebben M, Bockaert J. BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons. Eur J Pharmacol 1989;162:381-4.
81. Buchheit KH, Gamse R, Pfannkuche HJ. SDZ 205-557, a selective, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum. Naunyn Schmiedebergs Arch Pharmacol 1992;345:387-93.
82. Briejer MR, Akkermans LM, Meulemans AL, Lefebvre RA, Schuurkes JA. Cisapride and a structural analogue, R 76,186, are 5-hydroxytryptamine4 (5-HT4) receptor agonists on the guinea-pig colon ascendens. Naunyn Schmiedebergs Arch Pharmacol 1993;347:464-70.
83. Roth BL, Chuang DM. Multiple mechanisms of serotonergic signal transduction. Life Sci 1987;41:1051-64.
84. Claeysen S, Sebben M, Becamel C, Bockaert J, Dumuis A. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol 1999;55:910-20.
85. Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol 1989;340:403-10.
86. Torres GE, Holt IL, Andrade R. Antagonists of 5-HT4 receptor-mediated responses in adult hippocampal neurons. J Pharmacol Exp Ther 1994;271:255-61.
87. Bockaert J, Claeysen S, Sebben M, Dumuis A. 5-HT4 receptors: gene, transduction and effects on olfactory memory. Ann N Y Acad Sci 1998;861:1-15.
88. Matthes H, Boschert U, Amlaiky N, Grailhe R, Plassat J-L, Muscatelli F, et al. Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression and chromosomal localization. Mol Pharmacol 1993;43:313-19.
89. Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE. The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells. Eur J Pharmacol 1998;361:299-309.
90. Waeber C, Grailhe R, Yu XJ, Hen R, Moskowitz MA. Putative 5-ht5 receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravisation. Ann N Y Acad Sci 1998;861:85-90.
91. Hoyer D, Martin GR. Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav Brain Res 1996;73:263-8.
92. Saxena PR. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther 1995;66:339-68.
93. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43:320-7.
94. Shen Y, Monsma FJ, Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 1993;268:18200-4.
95. Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993;11:449-58.
96. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996;66:47-56.
97. Bourson A, Boess FG, Bos M, Sleight AJ. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol 1998;125:1562-6.
98. Boess FG, Riemer C, Bos M, Bentley J, Bourson A, Sleight AJ. The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol 1998;54:577-83.
99. Ward RP, Hamblin MW, Lachowicz JE, Hoffman BJ, Sibley DR, Dorsa DM. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 1995;64:1105-11.
100. Gustafson EL, Durkin MM, Bard JA, Zgombick J, Branchek TA. A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-ht7 receptor in rat brain. Br J Pharmacol 1996;117:657-66.
101. Shimizu M, Nishida A, Zensho H, Yamawaki S. Chronic antidepressant exposure enhances 5-hydroxytryptamine7 receptor-mediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes. J Pharmacol Exp Ther 1996;279:1551-8.
102. Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, et al. SB-224289 - a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol 1998;125:202-8.
103. Schlicker E, Fink K, Molderings GJ, Price GW, Duckworth M, Gaster L, et al. Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto-and heteroreceptors. Naunyn Schmiedebergs Arch Pharmacol 1997;356:321-7.
104. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, et al. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic durai inflammation model of migraine. Life Sci 1997;61:2117-26.